Monlunabant

N/A

Report date: 2024/05/30 10:36:03
NME

Base Information

Drug NameMonlunabant
Drug Alias NameINV-202MRI-1891NN9440–INV-202S-MRI-1891(-)-MRI-1891
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCannabinoid CB1 receptor inverse agonistsCannabinoid CB1 receptor antagonists
TargetsCannabinoid CB1 receptor
Therapy Area/IndicationsObesityMetabolic SyndromeMetabolic Diseases +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSerbia +[7] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesInversago Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesNovo Nordisk A/SInversago Pharma Inc
Inactive CompaniesN/A
Active IndicationsObesityMetabolic SyndromeMetabolic Diseases +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A